Alpha Cognition Inc. income statement
In fiscal 2025, Alpha Cognition Inc. reported revenue of $10.2m, operating income of −$22.7m (a -221.7% margin) and net income of −$20.7m, or −$1.18 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.
Income statement
| Quarter | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|
| Revenue | 3 | 2 | 3 | 3 | 4 | 6 |
| Cost of revenue | 0 | 0 | — | — | — | 0 |
| Gross profit | 3 | 1 | — | — | — | 6 |
| Research and development | 0 | 0 | 1 | 1 | 1 | 2 |
| Selling, general and administrative | 5 | 9 | 7 | 10 | 10 | 11 |
| Operating income | −3 | −8 | −5 | −8 | −8 | −8 |
| Interest expense | 0 | −0 | — | — | — | — |
| Net income | −2 | −13 | −1 | −7 | −6 | −9 |
| Diluted EPS | −$0.11 | −$0.82 | −$0.30 | −$0.31 | −$0.32 | −$0.40 |
| EBITDA | −3 | −8 | −5 | −8 | −8 | −8 |
Compare with peers
- Keros Therapeutics, Inc. income statement
- Alector, Inc. income statement
- Lineage Cell Therapeutics, Inc. income statement
- Proqr Therapeutics N.V. income statement
- Cytomx Therapeutics, Inc. income statement
Head to head: ACOG vs KROSACOG vs ALECACOG vs LCTX
More: Biotechnology stocks compared, Health Care sector, rankings of US companies